The Long and Winding Road to Warfarin Pharmacogenetic Testing

Journal of the American College of Cardiology

Volumn 55, Issue 25, 2010, Pages 2813-2815

  Ginsburg, Geoffrey S ^a   Voora, Deepak ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

comparative effectiveness; genotyping; pharmacogenomics; warfarin

Indexed keywords

ABACAVIR; CARDIOVASCULAR AGENT; CETUXIMAB; CLOPIDOGREL; CYTOCHROME P450 2C9; DABIGATRAN; HLA B ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; K RAS PROTEIN; PRASUGREL; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTIVIRAL THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON ADENOCARCINOMA; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG HYPERSENSITIVITY; DRUG MONITORING; EDITORIAL; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; HEALTH INSURANCE; HUMAN; INTERNATIONAL NORMALIZED RATIO; METHODOLOGY; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; SURVIVAL ANALYSIS; THROMBOEMBOLISM; WARFARIN;

EID: 77953308585     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.04.006     Document Type: Editorial

References (20)

1. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360 (2009) 753-764
2. Gage B., Eby C., Johnson J., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84 (2008) 326-331
3. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358 (2008) 999-1008
4. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
5. Flockhart D.A., O'Kane D., Williams M.S., et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10 (2008) 139-150
6. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116 (2007) 1563-1570
7. Caraco Y., Blotnick S., and Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83 (2007) 460-470
8. Eckman M.H., Rosand J., Greenberg S.M., and Gage B.F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150 (2009) 73-83
9. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008) 1757-1765
10. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358 (2008) 568-579
11. Epstein R.S., Moyer T.P., Aubert R.E., et al. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol 55 (2010) 2804-2812
12. Lenzini P.A., Grice G.R., Milligan P.E., et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 6 (2008) 1655-1662
13. Warfarin Dosing Algorithm. http://www.warfarindosing.org Accessed May 4, 2010
14. Centers for Medicare and Medicaid Services. Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R). http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp&id=218& Accessed March 25, 2010
15. Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007) 2429-2436
16. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119 (2009) 2553-2560
17. Voora D., Shah S.H., Spasojevic I., et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54 (2009) 1609-1616
18. Voora D., Shah S.H., Reed C.R., et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 1 (2008) 100-106
19. Iakoubova O.A., Sabatine M.S., Rowland C.M., et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 51 (2008) 449-455
20. Iakoubova O.A., Tong C.H., Rowland C.M., et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 51 (2008) 435-443